Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02237313
Other study ID # 2014/063/HP
Secondary ID 2014A0067740
Status Recruiting
Phase N/A
First received September 1, 2014
Last updated August 29, 2017
Start date July 2015
Est. completion date November 2018

Study information

Verified date August 2017
Source University Hospital, Rouen
Contact Pascal JOLY, Professor
Phone 2 32 88 68 41
Email pacal.joly@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The bullous pemphigoid treatment is based on corticosteroids continued for several years. Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at later stages of disease progression. Our hypothesis is that these episodes of vulnerability may be under four kinds of factors that may be connected to the plurality of the history of these patients, and the resources they can mobilize throughout this experience, generating inequality in management and "work" around the disease.


Description:

The originality of the project lies in its multidisciplinary approach (dermatology, psychology, sociology). No such study has yet been carried out in the pemphigus who has been the subject of a very small number of works in sociology or psychology. The only studies are studies of quality of life with no longitudinal follow-up. The perspective of qualitative and quantitative data, sociological and psychological approaches, should allow more innovative and adapted to the medico-social and psychological care of patients with pemphigus approaches. The purpose of this study is to identify the determinants leading to moments of vulnerability in the course of patients with pemphigus in order to be able to offer preventive or corrective actions to improve the experience of the disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date November 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient major

- Patients with pemphigus vulgaris, diagnosed on a combination of:

1. clinical signs and

2. histological image above basal epithelial detachment with intra acantholysis,

3. direct immunofluorescence showing deposition of Immunoglobulin G and / or C3 to the surface of keratinocytes

- Join a social security scheme

- patient has been informed and have signed consent to participate in the study

Exclusion Criteria:

- Person placed under judicial protection,

- Patient without liberty by administrative or judicial decision,

- Patient participating in another trial for the duration of monitoring.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
psychological support and therapeutic education program


Locations

Country Name City State
France Hôpital Avicenne Bobigny
France CHU de Clermont-Ferrand Hôpital d'Estaing Clermont-Ferrand
France CH du Mans le Mans
France CHRU de Lille Hôpital Claude Huriez Lille
France Hôpital La Timone, Assistance publique hôpitaux de Marseille-Aix Marseille
France Hôpital Haut-Lévêque Pessac
France Centre hospitalier de Cornouaille Quimper
France Hôpital Robert Debré, chu de Reims Reims
France University Hospital of Rouen Rouen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary analysis of vulnerability factors evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire 12 months
Secondary analysis of vulnerability factors evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire 6 months
Secondary assessment of anxiety, uncertainty, fear, coping strategies assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire 12 months
Secondary assessment of anxiety, uncertainty, fear, coping strategies assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05534776 - Validation of 5-Point Investigator Global Assessments for Pemphigus
Terminated NCT00278642 - Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders Phase 1
Not yet recruiting NCT05898308 - Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus Phase 4
Terminated NCT01559155 - Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Active, not recruiting NCT01974518 - Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Phase 3
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed NCT00283712 - Use of Infliximab for the Treatment of Pemphigus Vulgaris Phase 2
Not yet recruiting NCT06285435 - Coagulation Activation in Patients With Pemphigus
Completed NCT01299857 - Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Phase 3
Completed NCT00960713 - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders N/A
Completed NCT00213512 - Effect of Anti CD20 in Pemphigus Desease Phase 2/Phase 3
Active, not recruiting NCT04400994 - IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus Phase 2
Terminated NCT03075904 - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Phase 1/Phase 2
Terminated NCT03762265 - A Study of PRN1008 in Patients With Pemphigus Phase 3
Recruiting NCT02365675 - Wound Dressings for Pemphigus and Pemphigoid N/A
Recruiting NCT01338103 - Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex N/A
Active, not recruiting NCT00656656 - Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Phase 2
Completed NCT00127764 - European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Phase 2/Phase 3
Recruiting NCT01313923 - Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus Phase 0